The TMPRSS6 gene produces matriptase-2¹¹ matriptase-2
A type II transmembrane serine protease expressed primarily in liver cells that acts as the body's main brake on hepcidin production, the enzyme that keeps hepcidin — the master iron-regulatory hormone — in check. Most genetic research on TMPRSS6 has focused on the Ala736Val variant (rs855791), which sits in the enzyme's catalytic domain. But rs228921, located roughly 2 kilobases upstream of the TMPRSS6 transcription start site, tags a second, independent signal at this locus. This upstream variant operates through a different mechanism: instead of altering the enzyme's activity, it likely affects how much matriptase-2 protein the liver produces. The result, however, is similar — lower matriptase-2 output means less hepcidin suppression, higher hepcidin, and reduced iron absorption from the gut.

The Mechanism

Matriptase-2 normally cleaves hemojuvelin²² hemojuvelin
A membrane-bound co-receptor that activates the BMP/SMAD signaling cascade, which drives hepcidin gene transcription in hepatocytes from the surface of liver cells. By removing this coreceptor, matriptase-2 blocks the BMP/SMAD pathway³³ BMP/SMAD pathway
Bone morphogenetic protein / son of mothers against decapentaplegic — a signaling cascade that upregulates hepcidin transcription and reduces hepcidin secretion. When matriptase-2 is produced at lower levels — as may occur with the G allele at rs228921 — this suppression is less effective. Hepcidin levels rise, ferroportin on gut enterocytes is internalized and degraded, and less dietary iron crosses the gut wall into the bloodstream.

rs228921 sits in low linkage disequilibrium with rs855791 (r² < 0.1 in European and Indian Asian populations), confirming that it is an independent genetic signal rather than a proxy for the Ala736Val variant. This means the two variants can be studied and act together as additive genetic risk⁴⁴ additive genetic risk
When two independent variants at the same locus both predispose to lower iron status, carrying both can compound the effect. An individual who is GG at rs228921 and also AA at rs855791 carries risk at two independent locations in the TMPRSS6 gene.

The Evidence

The landmark genome-wide association study by Chambers et al.⁵⁵ Chambers et al.
Chambers JC et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet, 2009 — conducted in 16,001 individuals of European and Indian Asian ancestry — identified rs228921 as independently associated with hemoglobin levels at genome-wide significance (combined P = 1.9 × 10⁻¹⁰). The variant clustered with rs228918 and rs228919 in a separate haplotype block from the primary rs855791/rs4820268 cluster, confirming its independent contribution to iron phenotype variation.

A systematic review⁶⁶ systematic review
Gichohi-Wainaina WN et al. Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators. Genes Nutr, 2015 documented comparable minor allele frequencies for rs228921 across Caucasian (MAF ~0.41) and Indian Asian (MAF ~0.48) populations, with this variant included among the eight TMPRSS6 SNPs showing inter-ethnic differences in association with iron status indicators.

A study in female Black South African populations found that the rs228918/rs228921 GG haplotype was associated with lower odds of elevated soluble transferrin receptor (sTfR > 8.3 mg/L; OR: 0.79, 95% CI: 0.63–0.98), illustrating how the biological effect of this upstream variant depends on haplotype context and may differ across ancestries — a reminder that iron-related genetic associations are influenced by population-specific haplotype backgrounds.

Practical Actions

For carriers of one or two G alleles, the implications parallel those of rs855791 but are additive: reduced TMPRSS6 activity → elevated hepcidin → lower iron absorption efficiency. The practical response focuses on the same strategies that improve iron uptake in the face of high hepcidin: pairing non-heme iron sources with vitamin C, choosing heme iron when possible, avoiding absorption inhibitors at iron-containing meals, and monitoring iron stores with periodic ferritin and transferrin saturation testing.

If a supplement is needed, iron bisglycinate⁷⁷ iron bisglycinate
A chelated amino acid form of iron that is absorbed partly through peptide transporters (PEPT1), bypassing the ferroportin bottleneck that hepcidin controls. Also labeled chelated iron or gentle iron is preferable to ferrous sulfate because its absorption is less dependent on ferroportin. Every-other-day dosing maximizes fractional absorption by allowing hepcidin to reset between doses.

The combined genetic picture matters: if you also carry the risk allele at rs855791 (or rs4820268), the two independent TMPRSS6 signals compound your predisposition toward lower iron absorption, making monitoring more important.

Interactions

rs228921 and rs855791 are in low LD (r² < 0.1) and represent independent signals at the TMPRSS6 locus — they can co-occur in the same individual and their effects are additive. Carrying both risk alleles compounds the predisposition to lower iron status. rs228918, rs228919, and rs575620 form a tight haplotype cluster with rs228921 and are likely in near-complete LD with each other.

TMPRSS6 variants also interact with HFE variants⁸⁸ HFE variants
HFE encodes a protein involved in hepcidin signaling. Loss-of-function variants C282Y (rs1800562) and H63D (rs1799945) reduce hepcidin and cause iron overload in homozygotes. See rs1800562. In individuals with HFE hemochromatosis variants, a hepcidin-reducing TMPRSS6 variant would amplify iron loading; conversely, in HFE carriers the higher hepcidin from TMPRSS6 risk alleles partially offsets the HFE-driven reduction. These opposing effects mean the clinical interpretation depends on what HFE variants are co-present.

The rs2546890 variant sits approximately 2,000 base pairs upstream of the IL12B gene¹¹ IL12B gene
located at chromosome 5q33.3, encodes the p40 subunit shared by interleukin-12 and interleukin-23, within a non-coding RNA locus designated LOC285626. IL-12 and IL-23 are cytokines produced by dendritic cells and macrophages that act as master switches for adaptive immune responses: IL-12 drives naive T cells toward the Th1 (IFN-γ-producing) lineage, while IL-23 sustains the Th17 (IL-17-producing) lineage. Both arms are implicated in autoimmune demyelination, psoriatic inflammation, and immune-mediated liver disease. The rs2546890 A allele has been associated in large genome-wide studies with elevated risk of multiple sclerosis, psoriasis, and primary biliary cholangitis — three immunologically distinct diseases unified by shared IL-12/IL-23 pathway dysregulation.

The Mechanism

rs2546890 is annotated as a non-coding transcript variant in the LOC285626 locus. Its position in the IL12B upstream regulatory region places it within a genomic neighborhood that contains multiple independently replicated autoimmune susceptibility signals. The IL12B locus at 5q33.3 harbors several GWAS-identified variants (including rs6887695 in the upstream region and rs3212227 in the 3′ UTR) that form a risk haplotype functionally linked to elevated p40 subunit expression in monocytes and dendritic cells. Carriers of the IL12B risk haplotype show increased IL12B mRNA and protein in antigen-presenting cells, leading to higher serum IL-12 and a Th1-polarized immune milieu²² increased IL12B mRNA and protein in antigen-presenting cells, leading to higher serum IL-12 and a Th1-polarized immune milieu
The p40 subunit is shared by both IL-12 and IL-23 heterodimers, so expression changes affect both cytokine outputs simultaneously. rs2546890 is in linkage disequilibrium with variants in this regulatory haplotype, likely tagging the same functional effect — enhanced transcription factor access to the IL12B promoter region during innate immune activation.

The Evidence

The association of rs2546890 with multiple sclerosis has been established across multiple large GWAS cohorts. The 2011 International MS Genetics Consortium (IMSGC) study³³ 2011 International MS Genetics Consortium (IMSGC) study
Sawcer et al., Nature 2011, PMID 21833088 analysed 9,772 MS cases and 16,849 controls of European ancestry across 23 research groups and identified the IL12B locus region among at least 29 novel susceptibility signals. The 2019 IMSGC genomic map⁴⁴ 2019 IMSGC genomic map
International MS Genetics Consortium, Science 2019, PMID 31604244 expanded this to 47,429 MS cases and 68,374 controls, confirming rs2546890 among 200 autosomal susceptibility variants, with an odds ratio of approximately 1.11 (p = 1×10⁻¹¹). An independent Italian cohort study Leone et al., PLOS ONE 2013, PMID 23785401⁵⁵ Leone et al., PLOS ONE 2013, PMID 23785401 found that rs2546890 near IL12B was the only non-HLA variant significantly associated with cerebrospinal fluid oligoclonal bands — a biomarker of CNS-compartmentalised inflammation — in 1,115 Italian MS patients (OR 1.45, 95% CI 1.09–1.92), validated by in silico replication in Scandinavian and Belgian cohorts.

For psoriasis, the IL12B locus is one of the most robustly replicated susceptibility signals. GWAS Catalog records for rs2546890 show associations at p = 1×10⁻²⁰ (OR 1.54, 95% CI 1.32–1.79) and p = 3×10⁻³⁵ (OR 1.39, 95% CI 1.32–1.47) across separate European cohorts. Pharmacogenomic studies link rs2546890 to biologic treatment response: Ovejero-Benito et al., Pharmacogenomics 2017, PMID 28470127⁶⁶ Ovejero-Benito et al., Pharmacogenomics 2017, PMID 28470127 found association with etanercept response at 6 months (n=68), and the same group Pharmacogenomics 2018, PMID 29192552⁷⁷ Pharmacogenomics 2018, PMID 29192552 found that rs2546890 was among five SNPs associated with PASI75 response to adalimumab or infliximab at 3 months (n=95). For primary biliary cholangitis, an international GWAS meta-analysis Cordell et al., 2015, PMID 26394269⁸⁸ Cordell et al., 2015, PMID 26394269 identified the locus at p = 5×10⁻¹² (beta = 0.133). The convergence of three immunologically distinct conditions on the same variant underscores its role as a broad immune-regulatory signal rather than a disease-specific variant.

Practical Actions

For individuals carrying one or two A alleles, the primary actionable implications are: (1) heightened monitoring for early signs of MS, psoriasis, and autoimmune liver disease; (2) awareness of the pharmacogenomic relevance to IL-12/IL-23 pathway-targeting biologics. Ustekinumab (Stelara) targets the p40 subunit encoded by IL12B — the protein whose expression is amplified by the risk haplotype this variant tags. Pharmacogenomic studies show that IL12B genotype influences ustekinumab response in psoriasis, making this result clinically relevant for biologic selection. Similarly, IL-12/IL-23 pathway-blocking biologics used in MS (natalizumab does not target this pathway directly, but newer agents such as ofatumumab act upstream in the B-cell/innate immune cascade implicated by this locus) are of increasing relevance.

Interactions

rs2546890 acts within the broader IL12B susceptibility haplotype that includes rs6887695 (upstream) and rs3212227 (3′ UTR). Individuals carrying risk alleles at rs2546890 alongside the IL12B 3′ UTR risk haplotype (rs3212227) likely have compounding effects on p40 expression. The IL23R rs11209026 (R381Q) loss-of-function variant provides strong protection against MS, psoriasis, IBD, and ankylosing spondylitis by reducing IL-23 receptor signaling downstream of the p40-containing IL-23 heterodimer. Carrying both the rs2546890 A risk allele (elevated IL12B expression) and the IL23R rs11209026 protective A allele creates a partial antagonistic interaction that would benefit from compound action analysis. The existing IL12B SNP rs12188300 in GeneOps operates on a partially overlapping locus; individuals carrying risk alleles at both rs12188300 and rs2546890 likely have additive effects on IL-12/IL-23 pathway amplification.

CD14 is the first responder to bacterial invasion. Expressed on the surface of monocytes and macrophages¹¹ monocytes and macrophages
the frontline phagocytic cells of innate immunity, CD14 acts as a co-receptor that binds lipopolysaccharide (LPS) — the potent endotoxin coating the outer membrane of every gram-negative bacterium in your gut, on your skin, and in the environment. Once CD14 captures LPS, it hands it off to TLR4/MD-2²² TLR4/MD-2
Toll-like receptor 4, the signal-transducing partner that fires the NF-κB inflammatory cascade, triggering cytokine release and the full inflammatory response to bacterial threats.

The -159C>T promoter variant (rs2569190, also reported as -260C>T depending on the transcription start site used) is one of the most studied functional SNPs in immunogenetics. It sits in a GC-box element in the CD14 promoter³³ GC-box element in the CD14 promoter
a transcription factor binding site ~159 base pairs upstream of the coding sequence and changes how much CD14 protein your immune cells produce. The variant is notable for driving one of the clearest gene-environment interactions in all of allergy research.

The Mechanism

The T allele (reported as A on the plus strand in genome files; the gene is on the minus strand of chromosome 5) is associated with a functional impact on CD14 transcription⁴⁴ functional impact on CD14 transcription
In vivo chromatin immunoprecipitation shows twice as much RNA polymerase II recruited to the T-allele haplotype, indicating stronger transcription initiation, though allele-specific transcript quantification finds similar mRNA output between haplotypes. The net result is that TT homozygotes have significantly higher circulating soluble CD14 (sCD14)⁵⁵ TT homozygotes have significantly higher circulating soluble CD14 (sCD14)
sCD14 is shed from monocyte surfaces and acts as a soluble pattern-recognition molecule extending LPS detection to cells that don't express membrane CD14. CC homozygotes produce less sCD14 and have a more muted basal response to bacterial endotoxin.

This expression difference creates the paradox at the heart of the hygiene hypothesis: higher CD14 = more efficient LPS detection = stronger Th1 skewing = protection against allergic sensitization — but only when microbial exposure is high enough to exploit that capacity. In environments with low endotoxin load (urban living, formula feeding, no farm exposure), the T allele's higher CD14 expression may paradoxically drive heightened allergic responses by amplifying immune reactivity without the Th1-steering effect that requires persistent bacterial stimulation.

The Evidence

Baldini et al. 1999⁶⁶ Baldini et al. 1999
Original discovery in 481 children: TT homozygotes had significantly higher sCD14 and lower total IgE among skin-test-positive children (p=0.004) established that the T allele of CD14/-159 is the higher-expression variant and reduces IgE-mediated sensitization — but only in atopic children, implying a gene-environment gate.

The gene-environment interaction was definitively demonstrated by Simpson A et al. 2006⁷⁷ Simpson A et al. 2006
Study of 442 Manchester children showing opposite CD14 allele effects depending on farming exposure. In children with low endotoxin exposure, the C allele (GG genotype on plus strand) was the allergy risk genotype. In children with high endotoxin exposure (farm families), the T allele (AA on plus strand) became the risk genotype. The crossover was replicated across four independent populations (rural Europe, Manchester, Detroit, Barbados), with the most dramatic crossover effects seen in the high-contrast exposure settings.

A meta-analysis of 23 studies including 4,780 cases and 5,650 controls⁸⁸ A meta-analysis of 23 studies including 4,780 cases and 5,650 controls
BMC Medical Genetics 2011, PMID 21745379 found that when restricted to homogeneous atopic asthma phenotypes, the T allele is protective: TT vs CC OR = 0.67 (95% CI 0.54-0.84) and CT vs CC OR = 0.80 (95% CI 0.66-0.95), consistent with a codominant protective effect — in populations without stratification by endotoxin exposure.

Kerkhof et al. 2012⁹⁹ Kerkhof et al. 2012
JACI, PMID 21996339 pooled three allergy-prevention intervention cohorts and showed the genotype determines whether reducing microbial exposure in infancy helps or harms: interventions that decreased indoor allergen/endotoxin exposure were protective in CC children but increased atopy in TT children — a striking pharmacogenomic-style genotype-determines- direction effect.

For infectious disease, the T allele (AA genotype) consistently shows survival advantage. Mansur et al. 2015¹⁰¹⁰ Mansur et al. 2015
Prospective cohort of 417 sepsis patients, PMID 26020644 found that C-allele carriers had 23% 30-day mortality vs 13% for TT homozygotes, with the C allele remaining a significant independent covariate in multivariate Cox regression (HR 2.11, 95% CI 1.08-4.12, p=0.028). Higher sCD14 from the T allele appears to improve LPS clearance and dampen the cytokine storm cascade driving organ failure.

Conversely, for SARS-CoV-2, Pati et al. 2021¹¹¹¹ Pati et al. 2021
JID, PMID 33822099 found the T allele (higher CD14 expression) correlates with higher COVID-19 infection rates and mortality across European countries (r=0.57 and r=0.61 respectively), while the CC genotype was protective against severe SARS. This is consistent with the hygiene-hypothesis model: high CD14 may amplify inflammatory responses to novel viral-associated LPS signals or drive excessive innate immune activation.

Practical Actions

The actionable takeaway from this literature is not "which allele is good" — both have context-dependent advantages — but rather understanding how your genotype interacts with your microbial environment. GG (CC in papers) carriers benefit most from increasing microbial diversity; their lower-expression CD14 means they need richer bacterial stimulation to drive appropriate Th1 immune development and LPS tolerance. AA (TT) carriers already produce abundant CD14 and may be more sensitive to both high endotoxin environments and novel inflammatory triggers. For sepsis prevention, AA carriers appear inherently more resilient. For allergy prevention in low-endotoxin environments, GG carriers are at higher baseline risk and benefit most from microbial exposure strategies.

Probiotic strain selection matters for this SNP. Gram-negative probiotics and fermented foods containing LPS-like molecules (e.g. Bifidobacterium species, spore-forming Firmicutes) stimulate the CD14/TLR4 axis differently than gram-positive species with lipoteichoic acid. For GG carriers building Th1 tolerance, gram-negative-rich fermented foods provide endotoxin-tolerizing stimulation without excessive inflammatory drive.

Interactions

The most important interaction is with TLR4 (rs4986790, Asp299Gly)¹²¹² TLR4 (rs4986790, Asp299Gly)
TLR4 is the downstream signal transducer for LPS delivered by CD14. CD14 captures LPS and hands it to TLR4; variants in both genes affect the same LPS-sensing pathway and may have compounded effects. Individuals with low-CD14 expression (GG at rs2569190) combined with blunted TLR4 signaling (Asp299Gly at rs4986790) would have doubly impaired LPS recognition.

IL-1β (rs16944)¹³¹³ IL-1β (rs16944)
a downstream cytokine produced after TLR4 activation and [TNF-α (rs1800629) | another key effector cytokine in the LPS response] polymorphisms modify the magnitude of the downstream inflammatory response once CD14-mediated LPS recognition occurs. Combined low-CD14 (GG) with high-TNF (rs1800629 AA) may create discordant signaling — poor initial sensing but exaggerated response once threshold is crossed.

For the allergy interaction: the hygiene hypothesis gene-environment effect is most pronounced for TLR2 and TLR4 co-variants. Studies suggest that the farming protective effect on allergy operates through the CD14-TLR4-IL-12 axis, and variants in any of these genes modulate how robustly farm environments suppress IgE responses.

The glucocorticoid receptor, encoded by NR3C1 on chromosome 5, is the molecular sensor for cortisol — the body's primary stress hormone. When cortisol rises (in response to physical or psychological stress, illness, or metabolic disruption), it enters cells and binds to the glucocorticoid receptor, triggering a cascade of genomic effects that regulate inflammation, metabolism, blood pressure, and — critically — the hypothalamic-pituitary-adrenal (HPA) axis itself. This rs258750 variant, an intronic single nucleotide polymorphism at position c.2181+244 of the NR3C1 gene, tags a haplotype block that spans several well-studied NR3C1 functional variants including the 9beta polymorphism (rs6198) that alters GR-beta isoform production¹¹ including the 9beta polymorphism (rs6198) that alters GR-beta isoform production
The 9beta variant disrupts a 3' UTR sequence element that destabilizes mRNA, increasing the inactive GR-beta isoform. Carriers of the G allele at rs258750 appear in haplotype studies to tag reduced glucocorticoid receptor sensitivity, with measurable downstream effects on cortisol output, metabolic parameters, and stress physiology.

The Mechanism

The glucocorticoid receptor exists in two primary isoforms: GR-alpha, which is transcriptionally active and mediates cortisol's genomic effects, and GR-beta, an alternatively spliced isoform that acts as a dominant-negative inhibitor²² dominant-negative inhibitor
GR-beta forms dimers with GR-alpha, impairing its ability to bind glucocorticoid response elements of GR-alpha signaling. The rs258750 G allele tags a haplotype in the 3' region of NR3C1 that has been associated with increased GR-beta production relative to GR-alpha, thereby reducing the net glucocorticoid signaling response to circulating cortisol. The intronic position of rs258750 itself suggests it may influence splice site efficiency or regulatory element function within the complex multi-transcript NR3C1 locus.

For the reproductive axis, the consequences of altered glucocorticoid sensitivity are significant. Cortisol acts on hypothalamic neurons that control GnRH pulsatility³³ GnRH pulsatility
Gonadotropin-releasing hormone — the master pulse generator that drives LH and FSH release from the pituitary. Elevated cortisol directly suppresses GnRH pulse frequency and amplitude, reducing downstream LH and FSH secretion. In women with functional hypothalamic amenorrhea — a stress-induced cessation of ovulation — increased basal cortisol and blunted CRH responsiveness are hallmarks⁴⁴ In women with functional hypothalamic amenorrhea — a stress-induced cessation of ovulation — increased basal cortisol and blunted CRH responsiveness are hallmarks
Morrison et al. 2021 review of FHA pathophysiology. Reduced glucocorticoid receptor sensitivity in G allele carriers may partially buffer this HPA-to-HPG suppressive pathway, but it also alters the HPA axis's negative feedback dynamics, with complex consequences for both cortisol homeostasis and reproductive timing.

The Evidence

The NR3C1 9beta haplotype — which rs258750 appears to tag — has been studied across multiple phenotypes. Chung et al. 2009 studied GENOA families across three ethnic groups⁵⁵ Chung et al. 2009 studied GENOA families across three ethnic groups
Chung CC et al. J Clin Endocrinol Metab 2009 and found the 9beta variant in the NR3C1 3' UTR associated with multiple blood pressure measures in European-Americans, proposing that increased GR-beta production reduces net glucocorticoid receptor signaling and blood pressure regulation.

Metabolically, Trementino et al. 2012 studied 61 Cushing's syndrome patients⁶⁶ Trementino et al. 2012 studied 61 Cushing's syndrome patients
Trementino L et al. Eur J Endocrinol 2012 — people with chronically elevated cortisol — and found carriers of the 9beta haplotype were dramatically protected from developing type 2 diabetes (19% vs 68% prevalence, P=0.001). The proposed mechanism: reduced GR sensitivity attenuates cortisol's diabetogenic effects on glucose metabolism and insulin resistance. Similarly, Rodrigues et al. 2017 followed 131 adolescents for 5 years⁷⁷ Rodrigues et al. 2017 followed 131 adolescents for 5 years
Rodrigues DM et al. Appetite 2017 and found G allele carriers consumed less sugar, had lower insulin levels, better insulin sensitivity, and lower anxiety scores.

For cortisol output itself, Nordkap et al. 2022 studied 696 Danish men⁸⁸ Nordkap et al. 2022 studied 696 Danish men
Nordkap L et al. Psychoneuroendocrinology 2022 and found the 9beta minor allele (G allele) inversely correlated with hair cortisol concentration — a measure of long-term cortisol exposure — suggesting G allele carriers have dampened HPA axis output, possibly through impaired negative feedback. Castro-Vale et al. 2021⁹⁹ Castro-Vale et al. 2021
Castro-Vale I et al. J Psychiatr Res 2021 found the 9beta risk allele significantly associated with lifetime PTSD in male war veterans, with carriers having lower hair cortisol — consistent with HPA axis blunting that impairs adaptive stress responses.

Practical Implications

The G allele at rs258750 identifies a glucocorticoid receptor haplotype with demonstrably reduced cortisol sensitivity. For reproductive function, this creates competing effects: reduced HPA suppression of GnRH under moderate stress (potentially protective) versus altered cortisol feedback dynamics that may prolong stress responses. For women with G allele genotypes who experience stress-related cycle irregularities or subfertility, the NR3C1 background suggests the HPA-HPG interface is under altered glucocorticoid control, warranting evaluation of cortisol patterns alongside standard reproductive hormones.

For men, NR3C1 expression in peritubular cells, Leydig cells, and spermatogonia¹⁰¹⁰ NR3C1 expression in peritubular cells, Leydig cells, and spermatogonia
Nordkap et al. 2017 confirmed glucocorticoid receptor protein in multiple testicular cell types indicates that glucocorticoid signaling directly modulates testicular function. Altered GR sensitivity from NR3C1 haplotype variants may contribute to the documented link between psychological stress and impaired semen quality.

Interactions

rs6198 (NR3C1 9beta): The functionally characterized 3' UTR variant (rs6198) is the primary mechanistic variant in the haplotype block that rs258750 appears to tag. Studies using rs6198 as the direct genotype provide the mechanistic foundation for this intronic variant's associations. The rs258750 G allele is likely in partial LD with the rs6198 G allele.

rs41423247 (BclI): The BclI polymorphism is the most studied NR3C1 variant for reproductive outcomes. Nordkap et al. 2017¹¹¹¹ Nordkap et al. 2017
Nordkap L et al. Andrology 2017 found BclI heterozygotes had superior semen parameters (sperm motility, inhibin B, lower FSH) in an over-dominant pattern. The rs258750 variant and BclI are in the same NR3C1 gene and may form compound haplotypes with additive or epistatic effects on overall glucocorticoid sensitivity.

Von Willebrand factor (VWF) is a molecular intermediary between damaged vessel walls and circulating platelets. When an endothelial surface tears, collagen fibres in the extracellular matrix are exposed. VWF must grip that collagen through its A3 domain¹¹ A3 domain
The A3 domain occupies residues 1686-1874 of mature VWF; it folds into a classical von Willebrand A barrel structure that positions a surface groove to engage fibrillar collagen types I and III before platelets can be recruited to seal the wound. The W1745C variant — a tryptophan-to-cysteine substitution at position 1745 — sits within this collagen-binding groove and dismantles exactly that one function without visibly disturbing anything else.

The consequence is a bleeding disorder that routine haematology labs routinely miss. VWF antigen levels are normal. The most widely used functional test — the ristocetin cofactor assay (VWF:RCo), which measures platelet-binding — is normal. Multimers are normal. Only a dedicated VWF collagen-binding assay (VWF:CB)²² VWF collagen-binding assay (VWF:CB)
Measures how well VWF adheres to immobilised type I or III collagen; the single most sensitive assay for detecting isolated A3-domain defects reveals the defect. This condition is classified as von Willebrand disease type 2M³³ von Willebrand disease type 2M
The "M" stands for multimer-independent — the bleeding defect does not arise from loss of high-molecular-weight multimers but from a qualitative functional impairment of platelet adhesion, also designated type 2CB (collagen-binding subtype). Carriers can bleed significantly from dental extractions, surgery, and childbirth while appearing fully normal on pre-operative screening panels.

The Mechanism

The VWF A3 domain adopts a von Willebrand A fold⁴⁴ von Willebrand A fold
A barrel-like beta-sheet common to VWF domains, integrins, and complement proteins; the convex face presents the collagen-binding groove with critical hydrophobic and polar contacts that presents a curved surface groove for collagen engagement. Tryptophan 1745 provides a bulky aromatic side chain that makes hydrophobic and geometric contacts within the collagen-binding interface. Substituting cysteine — a much smaller, flexible, sulphydryl- bearing residue — eliminates those contacts and likely introduces a free thiol that could form aberrant disulphide bonds, destabilising the local groove architecture without disrupting the overall protein fold, multimerisation, or Factor VIII binding capacity.

Recombinant W1745C VWF expressed in HEK293T cells by Riddell et al. showed a pronounced collagen-binding defect to both type I and type III collagen⁵⁵ Riddell et al. showed a pronounced collagen-binding defect to both type I and type III collagen
Riddell AF et al., Blood 2009; mutations were reproduced by site-directed mutagenesis and characterised in vitro; VWF:CB was severely reduced while multimer analysis was indistinguishable from wild-type, while VWF multimer patterns were indistinguishable from wild-type. Among the three A3-domain mutations characterised in that study, W1745C and S1783A both caused pronounced binding defects to both collagen types, whereas S1731T primarily affected type I collagen — demonstrating that distinct residues in the A3 groove mediate binding to the two collagen subtypes.

The Evidence

The primary characterisation is Riddell et al., Blood 2009⁶⁶ Riddell et al., Blood 2009
Riddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, Sutherland M, Laffan MA, McKinnon TAJ. Blood. 2009 Oct 15;114(16):3489-96 — three families investigated; W1745C identified in one individual in compound heterozygosity with R760H; site-directed mutagenesis confirmed A3-domain collagen-binding loss with normal multimers. The individual carrying W1745C had compound heterozygosity (W1745C on one allele, R760H on the other) and showed a VWF:CB/VWF:Ag ratio of 0.3 — severely reduced, consistent with a dominant collagen-binding defect — alongside a normal multimer pattern and normal VWF:RCo. The authors proposed that isolated collagen-binding defects should be classified as a distinct VWD subtype, laying the clinical-diagnostic framework that would eventually produce the type 2M/2CB designation.

ClinVar variation 100421⁷⁷ ClinVar variation 100421
ClinGen Von Willebrand Disease Variant Curation Expert Panel classification; last evaluated August 13, 2024; four-star review status; criteria PS3, PP4, PM2_Supporting, PP3 applied classifies W1745C as Likely Pathogenic for VWD type 2M following expert panel review in August 2024. The evidence supporting classification includes the in vitro collagen-binding data, the clinical observation of decreased VWF:CB/VWF:Ag ratio in the index patient, and supporting computational evidence (PP3). The variant is entirely absent from gnomAD population databases (one allele observed in 805,812 in gnomAD exomes — effectively zero population frequency), consistent with strong negative selection.

The importance of including VWF:CB in the diagnostic workup for any bleeding history is established by Favaloro and Mohammed, 2014⁸⁸ Favaloro and Mohammed, 2014
Favaloro EJ, Mohammed S. Thromb Res 135(6):1307-16, 2014 — comparative evaluation of VWF assay platforms; VWF:CB was most discrepant from VWF:RCo precisely in type 2M/2CB patients, confirming its essential role in detecting A3-domain collagen-binding defects. Without a specific collagen-binding assay, this mutation class is systematically undetectable by standard VWD laboratory panels.

Practical Actions

For any carrier, the immediate priority is to make a concealed diagnosis visible: the VWF:CB assay must be explicitly requested. Once the defect is documented, the key clinical decision involves haemostatic coverage for procedures. DDAVP (desmopressin) — the first-line agent for type 1 and many type 2 VWD variants — releases endogenous VWF stores from endothelial Weibel-Palade bodies, but the released VWF carries the W1745C mutation and is expected to bind collagen poorly. VWF concentrate (Humate-P, Wilate, or recombinant VWF such as Vonvendi) provides functionally normal collagen-binding VWF and is the appropriate haemostatic cover when a carrier needs a procedure.

Interactions

W1745C was co-identified alongside S1783A at rs267607353⁹⁹ S1783A at rs267607353
The companion A3-domain variant from the same 2009 characterisation study; also causes pronounced binding defect to both type I and III collagen; OMIM 613160.0042 — another A3-domain variant in the same collagen-binding groove. Compound heterozygosity of two A3-domain defects (e.g. W1745C on one allele and S1783A or another A3 variant on the other) would be expected to produce near-complete loss of collagen-binding activity and a more severe bleeding phenotype, though no published case of such a combination has been described. The index patient carrying W1745C was compound heterozygous with R760H, a type 1 VWD variant in the D3 domain — this combination reduced VWF:CB/VWF:Ag to 0.3 — suggesting that heterozygous W1745C alone may not fully account for all bleeding symptom severity when other VWF variants are co-inherited. ABO blood group (O type lowers VWF levels ~25%) is the standard VWF modifier, but ABO effects operate through VWF clearance rate, not collagen binding, so the ABO interaction is less clinically relevant for this qualitative A3-domain defect than it is for quantitative VWD variants.

Interleukin-10 (IL-10) is the immune system's master anti-inflammatory cytokine — the molecular signal that tells an activated immune response to stand down. When IL-10 production is reduced, inflammatory reactions in the gut, joints, and other tissues run longer and harder than they should. rs3024505 sits approximately 5 kilobases downstream of the IL10 gene's 3' end on chromosome 1q32.1¹¹ chromosome 1q32.1
The long arm of chromosome 1, a region with dense immune gene content and one of the most robustly replicated IBD susceptibility loci in the human genome. It is the lead GWAS signal at the IL10 locus for inflammatory bowel disease and has been associated with systemic lupus erythematosus, Sjögren's syndrome, and other autoimmune conditions.

IL10 is encoded on the minus (reverse) strand of chromosome 1. Genome files report alleles on the plus strand — so while published papers describe this as a C/T polymorphism (coding-strand notation), plus-strand genome files use G and A. The common G allele corresponds to the protective C allele in papers; the risk A allele is what papers call the T allele. All genotype keys here use plus-strand notation as reported by genome files.

The Mechanism

rs3024505 lies within an enhancer element²² enhancer element
A non-coding DNA sequence that boosts the transcriptional activity of nearby genes; enhancers can act over long distances by looping toward gene promoters that augments IL10 promoter activity, particularly in B cells. The common G allele (coding-strand C) creates a functional binding site for the transcription factor STAT3, which drives IL10 expression when immune cells are activated. The risk A allele (coding-strand T) disrupts this STAT3 binding site — luciferase reporter assays in stimulated pro-B cell lines confirmed a significant reduction in enhancer activity for the A variant compared to G.

This mechanism explains why rs3024505 is an expression quantitative trait locus (eQTL)³³ expression quantitative trait locus (eQTL)
A genetic variant that predicts the expression level of a nearby gene, confirmed in multiple immune cell types for IL10: carriers of the A allele produce less IL-10 per stimulated B cell. Lower IL-10 shifts the immune environment toward a more pro-inflammatory baseline. In the gut mucosa, inadequate IL-10 allows the normal commensal microbiome to trigger unresolved inflammatory responses — the fundamental driver of both Crohn's disease and ulcerative colitis. In systemic autoimmunity, impaired B cell IL-10 production removes a critical brake on autoreactive immune cell activation.

The Evidence

rs3024505 was first identified as a genome-wide significant UC susceptibility locus in the landmark 2008 GWAS at chromosome 1q32.1 that implicated IL10 in inflammatory bowel disease. The lead signal pointed directly to the IL10 downstream region as central to IBD pathogenesis.

A Danish case-control study of 336 CD patients, 498 UC patients, and 779 healthy controls⁴⁴ of 336 CD patients, 498 UC patients, and 779 healthy controls
Holt et al. 2010, The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohn's disease in a Danish case-control study, BMC Medical Genetics provided the clearest genotype-level data. Heterozygous CT carriers had OR = 1.31 for CD (p = 0.07) and OR = 1.34 for UC (p = 0.02). Homozygous TT carriers (corresponding to AA on the plus strand) showed substantially higher risk: OR = 2.48 for CD (95% CI 1.27–4.84, p = 0.01) and OR = 2.31 for UC (95% CI 1.27–4.20, p = 0.01). The combined CT+TT group reached OR = 1.40 for CD (p = 0.02) and OR = 1.43 for UC (p = 0.004). The T allele frequency in Danish controls was 18%.

A meta-analysis of 13 studies covering 8,552 IBD cases and 12,830 controls⁵⁵ of 13 studies covering 8,552 IBD cases and 12,830 controls
Gu et al. 2021, Association between IL-10 rs3024505 and susceptibility to inflammatory bowel disease: A systematic review and meta-analysis, Cytokine confirmed strong and consistent association across European populations: OR = 1.37 (95% CI 1.30–1.45) under the allelic model, OR = 2.06 (95% CI 1.74–2.45) under the recessive model, and OR = 2.25 (95% CI 1.89–2.67) for homozygous TT vs. CC (all p < 0.00001).

A Serbian case-control study of 107 CD patients, 99 UC patients, and 255 controls⁶⁶ of 107 CD patients, 99 UC patients, and 255 controls
Simovic et al. 2016, Downstream IL10 polymorphism associated with Crohn's disease in Serbian IBD patients, Inflammatory Bowel Diseases replicated the CD association and added a clinical nuance: carriers of the protective C allele had significantly increased risk of anemia and stricturing or penetrating disease behavior, illustrating how this locus influences not just susceptibility but also disease phenotype.

Beyond IBD, rs3024505 has been associated with systemic lupus erythematosus and Sjögren's syndrome (OR = 1.52, p = 0.025 for Sjögren's susceptibility), consistent with the variant's role in B cell IL-10 regulation across multiple autoimmune contexts.

The 2024 mechanistic study using reporter assays and chromatin immunoprecipitation in human B cell lines⁷⁷ using reporter assays and chromatin immunoprecipitation in human B cell lines
Uvarova et al. 2024, Autoimmunity-Associated SNP rs3024505 Disrupts STAT3 Binding in B Cells, Leading to IL10 Dysregulation, International Journal of Molecular Sciences provided the first direct functional explanation: the variant creates or destroys a STAT3 recognition sequence, giving rs3024505 a clear molecular mechanism — rare for a non-coding GWAS SNP.

Practical Actions

The A allele's functional effect on IL-10 production is concentrated in B cells but has downstream consequences for the entire mucosal and systemic immune environment. Anti-inflammatory nutritional strategies that upregulate IL-10 through independent pathways — particularly omega-3 fatty acids (EPA/DHA) and vitamin D — can partially compensate. EPA and DHA stimulate IL-10 production in macrophages and regulatory T cells via PPAR-γ activation; vitamin D drives IL-10 expression in Treg cells independently of STAT3. Neither substitutes for STAT3-driven B cell IL-10, but they reduce the overall inflammatory burden that low IL-10 producers carry.

For anyone with the AA genotype and gut symptoms, early gastroenterological evaluation is warranted. The diagnostic delay for IBD averages 1–3 years, and genetic risk awareness can prompt earlier endoscopic investigation before complications develop. Calprotectin testing offers a non-invasive first screen to distinguish gut inflammation from functional disorders.

Interactions

rs3024505 operates in parallel with the IL10 promoter haplotype system (rs1800896, rs1800871, rs1800872) and the intronic variant rs3024491, each of which independently regulates IL10 transcription from different regulatory elements. Carriers of both the downstream A allele at rs3024505 and a low-producing promoter haplotype face stacked reductions in IL-10 from multiple regulatory levels — a combined low-producer state that is likely additive for IBD risk and autoimmune susceptibility, though direct compound studies are limited.

Your skin's outermost layer — the stratum corneum — acts as a physical barrier keeping allergens and microbes out while locking moisture in. The protein that holds this barrier together is filaggrin¹¹ filaggrin
from "filament-aggregating protein", encoded by the FLG gene on chromosome 1q21.3. When FLG function is reduced, the skin barrier becomes leaky: water escapes, allergens penetrate, and the immune system is chronically primed for inflammation. rs3126085 is an intronic regulatory variant that influences FLG gene expression — the A allele is associated with reduced filaggrin production and elevated atopic dermatitis (eczema) risk.

rs3126085 sits in an intronic region of FLG-AS1, a non-coding antisense RNA gene adjacent to the FLG coding locus on chromosome 1q21.3. The variant acts as an expression quantitative trait locus (eQTL)²² expression quantitative trait locus (eQTL)
genetic variant that predicts gene expression level: the A allele is associated with a statistically significant reduction in FLG mRNA levels in sun-exposed skin (β = −0.22, p = 3.7×10⁻⁸). Lower filaggrin output means reduced production of the natural moisturizing factor (NMF)³³ natural moisturizing factor (NMF)
hygroscopic amino acids released when filaggrin is degraded in the stratum corneum, the molecules that bind water and maintain proper skin acidity. The downstream effects include elevated transepidermal water loss (TEWL), impaired antimicrobial defense, and increased penetration of environmental allergens — the classic triad of atopic dermatitis pathogenesis.

The strongest evidence comes from a GWAS of atopic dermatitis in the Chinese Han population⁴⁴ GWAS of atopic dermatitis in the Chinese Han population
1,012 cases and 1,362 controls with replication in 3,624 cases and 12,197 controls, which replicated the FLG locus with high confidence (P_combined = 5.90×10⁻¹², OR = 0.82 for the protective G allele). The same study extended findings to a German replication cohort (1,806 cases, 3,256 controls), confirming cross-ethnic relevance. Notably, rs3126085 is in strong linkage disequilibrium with the Chinese FLG null mutation c.3321delA (D′ = 0.976), meaning it partly tags a more penetrant loss-of-function allele; the null mutation itself carries a substantially higher OR (3.37).

A Russian Caucasian population study⁵⁵ Russian Caucasian population study
women only association; no association in men found the A allele associated with AD with OR = 1.22 in the overall population and OR = 1.69–1.79 in specific genetic models within the female subgroup. This sex-specific signal may reflect hormonal modulation of FLG expression, as estrogen influences keratinocyte differentiation and filaggrin production.

A four-variant interaction study in Chinese Han⁶⁶ four-variant interaction study in Chinese Han
OR up to 1.79 for A carriers across multiple genetic models showed that rs3126085 interacts epistatically with three other FLG regulatory SNPs (rs12144049, rs471144, rs4363385), with combined genotypes conferring substantially higher AD risk than any single variant alone.

Functional annotation confirms regulatory significance: the A allele shows histone modification marks consistent with enhancer activity and disrupts binding sites for the transcription factors Foxp3 and TEF, both of which influence immune tolerance and skin differentiation pathways.

Carrying the A allele — particularly in the AA homozygous state — indicates a genetically weaker skin barrier with reduced capacity for filaggrin-dependent moisturization. This does not mean you will develop eczema, but it substantially shifts the probability, especially under conditions of environmental challenge (dry climates, harsh detergents, certain fabrics, allergen exposure). The key insight is actionable: a compromised genetic barrier can be compensated with a consistent topical routine targeting the same pathways that filaggrin normally maintains.

Ceramide-containing moisturizers are particularly relevant here. Filaggrin deficiency is associated with ceramide depletion in the stratum corneum, and barrier repair emollients containing the physiologic lipid trio⁷⁷ barrier repair emollients containing the physiologic lipid trio
ceramide + cholesterol + free fatty acids in approximately equimolar ratio have been shown to normalize barrier function in atopic skin. Bland, fragrance-free cleansers that do not strip ceramides, applied within three minutes of bathing ("soak and seal"), are a cornerstone of guideline-recommended AD prevention.

rs3126085 operates as part of a broader haplotype block in the FLG/HRNR/CRNN locus at 1q21.3, where multiple variants interact. The most clinically significant combination involves concurrent carriage of FLG null alleles such as rs558269137 (2282del4) and rs61816761 (R501X): compound heterozygotes carrying both a null allele and the rs3126085 A allele face near-complete filaggrin deficiency, phenotypically equivalent to homozygous null status. The rs3126085 A allele also interacts with rs12144049, rs471144, and rs4363385 in pairwise and three-way epistatic models (see key references), with combined risk approaching 1.79-fold.

Every time a cell divides, its DNA faces the risk of double-strand breaks — the most dangerous class of DNA damage, capable of triggering chromosomal rearrangement or cell death if left unrepaired. The primordial follicle pool that determines a woman's reproductive lifespan is exquisitely sensitive to this damage: follicle cells that cannot repair DNA accurately are eliminated by apoptosis, gradually depleting the reserve that supports fertility and hormonal function. UIMC1¹¹ UIMC1
also known as RAP80 — Receptor-Associated Protein 80; encodes the ubiquitin-binding scaffold subunit of the BRCA1-A deubiquitin complex at DNA damage sites sits at the centre of this repair machinery. The rs353478 variant in an intron of UIMC1 emerged from the largest-ever GWAS of age at natural menopause as one of the strongest signals in the study — implicating this DNA repair checkpoint in the pace of ovarian ageing.

The Mechanism

When a double-strand break occurs, the histone E3 ligase RNF8 attaches [Lys63-linked ubiquitin chains | K63-linked polyubiquitin; a non-degradative ubiquitin signal that serves as a molecular scaffold for recruiting repair factors, as opposed to K48-linked chains which tag proteins for proteasomal degradation] to histones H2A and H2AX in the chromatin surrounding the break. RAP80 (UIMC1) contains tandem ubiquitin-interacting motifs (UIMs) that bind these K63-linked chains with high specificity, anchoring the entire BRCA1-A complex — BRCA1, BARD1, Abraxas, BRCC36, and KIAA0157 — directly to the damage site.

Recent work has revealed that RAP80 does not simply act as a passive scaffold. Qin et al. 2023²² Qin et al. 2023
RAP80 phase separation at DNA double-strand break promotes BRCA1 recruitment. Nucleic Acids Research, 51:10487–10503 showed that RAP80's intrinsically disordered N-terminal region drives liquid-liquid phase separation at break sites, forming dynamic condensates that concentrate BRCA1 and enhance repair efficiency. Disrupting this condensation — by mutating the IDR or blocking ubiquitin binding — significantly impaired homologous recombination and increased radiation sensitivity. Separately, Tang et al. 2024³³ Tang et al. 2024
DOT1L-mediated RAP80 methylation promotes BRCA1 recruitment to elicit DNA repair. PNAS, 121:e2401785121 demonstrated that the methyltransferase DOT1L must first methylate specific RAP80 lysine residues before RAP80 can engage ubiquitinated H2A — adding a post-translational regulatory layer to BRCA1-A complex assembly.

Although rs353478 is intronic and does not alter the RAP80 protein sequence, intronic variants can modulate splicing efficiency, transcript abundance, and isoform ratios. The T allele at this position tags a haplotype within UIMC1 that appears, across many thousands of women, to be associated with a modestly reduced capacity to maintain ovarian follicle DNA integrity — accelerating the pace at which the primordial follicle pool is depleted.

The Evidence

The definitive evidence comes from Ruth et al. 2021⁴⁴ Ruth et al. 2021
Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596:393–397, a GWAS of 201,323 women across 35 studies. The rs353478-C allele was associated with later age at natural menopause at beta = +0.298 years per allele (p = 3 × 10⁻²⁶⁸), placing the UIMC1 locus among the top three effect sizes in the entire study. The authors systematically enriched for DNA damage response genes among the top menopause loci, confirming that RAP80/BRCA1-A pathway integrity is a genuine determinant of the rate of ovarian ageing — not a GWAS artifact.

The UIMC1/5q35.2 locus was first detected in an earlier, smaller GWAS by He et al. 2009⁵⁵ He et al. 2009
Nature Genetics 41:646–650 in 17,438 women, reaching genome-wide significance alongside three other loci (MCM8, BRSK1, SYCP2L), all of which are now understood to participate in meiotic DNA repair or chromosome segregation fidelity. The biological coherence of this cluster — ovarian ageing GWAS hits enriched in DNA repair genes — provided the mechanistic logic that the 2021 mega-analysis confirmed at scale.

Practical Implications

For TT homozygotes, the T allele reduces each copy's contribution to ovarian reserve maintenance, on average compressing the reproductive window by approximately 0.6 years (two alleles × 0.298 years) relative to CC homozygotes. At the population level this is statistically clear; for individuals it means a slight shift in the probability distribution of menopausal timing, not a fixed outcome. The effect is meaningful when combined with other ovarian reserve markers and life circumstances.

The practical implications center on fertility timing awareness, ovarian reserve monitoring, and nutritional support for DNA repair pathways. Folate, vitamin B12, and zinc are cofactors in DNA synthesis and repair; ensuring adequate status of these micronutrients supports the cellular machinery that UIMC1 participates in. These supplements do not reverse the genetic variant's effect, but they remove avoidable nutritional bottlenecks from the same repair pathways.

Interactions

rs16991615 (MCM8): The MCM8 minichromosome maintenance helicase is required for meiotic DNA repair in oocytes. MCM8 rs16991615 is one of the most replicated ANM GWAS loci and, like rs353478, acts through DNA repair pathway integrity. Women carrying risk alleles at both UIMC1 and MCM8 may experience compounded effects on ovarian reserve depletion rate, as the two genes operate at adjacent steps in the homologous recombination pathway — BRCA1-A recruitment (UIMC1) and helicase-mediated strand unwinding for repair synthesis (MCM8).

rs2303369 (BRSK1): The brain-specific serine/threonine kinase BRSK1 regulates the DNA damage checkpoint in meiotic cells. The BRSK1 locus at 19q13.42 was identified alongside UIMC1 in the He et al. 2009 GWAS and confirmed in Ruth 2021. A compound action for women carrying risk alleles at both UIMC1 and BRSK1 would centre on earlier ovarian reserve assessment and intensified DNA repair nutrient support, as both variants converge on the fidelity of meiotic double-strand break resolution. Evidence for the combined effect is indirect (co-identification in GWAS enrichment analyses rather than formal interaction testing); a supervisor compound action at moderate evidence level would be appropriate.

Every day, reactive oxygen species assault your DNA, creating a specific form of damage called 8-oxoguanine¹¹ 8-oxoguanine
8-oxo-7,8-dihydroguanine (8-oxoG), one of the most common and mutagenic forms of oxidative DNA damage; it can mispair with adenine during replication, causing G:C to T:A transversion mutations (8-oxoG). Left uncorrected, 8-oxoG pairs with adenine instead of cytosine during DNA replication, producing permanent G:C to T:A transversion mutations²² transversion mutations
A type of point mutation where a purine is replaced by a pyrimidine or vice versa; transversions are more disruptive than transitions because they swap the chemical class of the base. The MUTYH gene encodes a DNA glycosylase that sits on the front line of base excision repair³³ base excision repair
A DNA repair pathway that fixes small, non-helix-distorting lesions; a glycosylase removes the damaged base, then downstream enzymes cut the backbone and fill in the correct nucleotide (BER), removing adenines that have been misincorporated opposite 8-oxoG. Without functional MUTYH, these transversion mutations accumulate — particularly in the APC tumor suppressor gene — setting the stage for colorectal cancer.

The Mechanism

The G396D variant (rs36053993) substitutes glycine with aspartate at position 396 of the MUTYH protein, located within the nudix hydrolase domain⁴⁴ nudix hydrolase domain
A catalytic domain found in a superfamily of enzymes that cleave nucleoside diphosphates; in MUTYH, this domain is critical for recognizing and excising mismatched adenines essential for substrate recognition and catalytic activity. This missense change substantially reduces the enzyme's ability to recognize and excise adenine mismatched with 8-oxoguanine. Functional studies show the G396D protein retains roughly 2% of normal glycosylase activity in vitro.

MUTYH-Associated Polyposis (MAP) follows autosomal recessive inheritance⁵⁵ autosomal recessive inheritance
Both copies of the gene must carry a pathogenic variant for the full disease phenotype; carriers with one mutant copy are largely protected by their remaining functional allele. Individuals with two pathogenic MUTYH alleles (biallelic carriers) develop tens to hundreds of colorectal adenomatous polyps, typically presenting between ages 40 and 60. Heterozygous carriers retain one fully functional copy and have near-normal DNA repair capacity.

The Evidence

The landmark 2002 discovery⁶⁶ landmark 2002 discovery
Al-Tassan N et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet, 2002 by Al-Tassan and colleagues first linked biallelic MUTYH mutations to familial adenomatous polyposis with a characteristic excess of somatic G:C to T:A transversions in the APC gene. This established a novel mechanism for colorectal cancer: defective base excision repair leading to a specific mutational signature.

A large-scale meta-analysis by Theodoratou et al.⁷⁷ large-scale meta-analysis by Theodoratou et al.
Theodoratou E et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer, 2010 pooling data from multiple cohorts found that biallelic MUTYH carriers have a 28-fold increased risk (95% CI 6.95-115) for colorectal cancer, while monoallelic (heterozygous) Y179C carriers have an OR of 1.34 — a modest elevation that varies by variant.

A retrospective cohort study by Nieuwenhuis et al.⁸⁸ retrospective cohort study by Nieuwenhuis et al.
Nieuwenhuis MH et al. Evidence for accelerated colorectal adenoma-carcinoma progression in MUTYH-associated polyposis. Gut, 2012 calculated a cumulative colorectal cancer risk of 63% by age 60 for biallelic MUTYH carriers in a retrospective cohort, underscoring the critical importance of early and regular colonoscopy.

For heterozygous carriers, a multisite case-control study by Cleary et al.⁹⁹ multisite case-control study by Cleary et al.
Cleary SP et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology, 2009 found an adjusted OR of 1.48 (95% CI 1.02-2.16) for CRC, confirming that heterozygous carrier status confers a small but real increase in risk beyond the general population.

G396D and Y179C (rs34612342)¹⁰¹⁰ Y179C (rs34612342)
The most common MUTYH pathogenic variant in Europeans, accounting for roughly 50-55% of all pathogenic MUTYH alleles; G396D accounts for approximately 25-30% together account for approximately 75-85% of all pathogenic MUTYH alleles in European populations, making them the primary targets for clinical screening.

Practical Implications

For GG individuals: both copies of MUTYH function normally. Your base excision repair pathway handles oxidative DNA damage effectively at this locus.

For AG (heterozygous carrier) individuals: you carry one non-functional copy of MUTYH. Your remaining functional allele provides adequate DNA repair capacity. The primary concern is reproductive — there is a risk of passing the variant to children. If your partner also carries a MUTYH pathogenic variant, each child has a 25% chance of being biallelic. A modest CRC risk elevation (OR ~1.2) has been observed in carriers. Standard-age colonoscopy screening is sufficient, though starting at age 40 rather than 45 is reasonable given the carrier status.

For AA (biallelic) individuals: you have MUTYH-Associated Polyposis. Current ACG/NCCN guidelines¹¹¹¹ ACG/NCCN guidelines
Syngal S et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol, 2015 recommend colonoscopy every 1-2 years starting at age 25-30. If polyps are found, annual colonoscopy with polypectomy is indicated. Colectomy may be necessary if polyp burden becomes unmanageable endoscopically. Upper endoscopy for duodenal adenomas should begin at age 30-35 and be repeated every 1-5 years depending on findings.

Interactions

The most important interaction is with Y179C (rs34612342), the other common MUTYH pathogenic variant. Compound heterozygosity — carrying one G396D allele and one Y179C allele — produces the same MAP phenotype as homozygosity for either variant alone. If a user carries AG at rs36053993 (G396D carrier) and is also heterozygous for rs34612342 (Y179C carrier), they are effectively biallelic for MUTYH and should follow the full MAP surveillance protocol. This compound heterozygous state accounts for a significant proportion of MAP cases, since many affected individuals carry one of each variant rather than two copies of the same one.

BANK1 (B-cell scaffold protein with ankyrin repeats 1) is a signaling hub expressed exclusively in B cells. It connects the B-cell receptor (BCR) to downstream calcium mobilization by scaffolding LYN kinase, IP3 receptors, and PLCγ2 into a signaling complex that determines how strongly a B cell responds to antigen. Three functional variants in BANK1 contribute independently to autoimmune risk. The best-known is rs10516487 (R61H), which affects the N-terminal scaffold domain. The second is rs17266594, an intronic branch-point SNP affecting splicing. The third — rs3733197, the A383T variant — is located in the ankyrin repeat domain¹¹ ankyrin repeat domain
The ankyrin domain (amino acids ~309–402) mediates protein-protein interactions that position BANK1's signaling partners within the BCR complex, a structurally distinct region from both of the other variants. A383T is notable for its breadth: it has been associated with lupus, rheumatoid arthritis, systemic sclerosis, inflammatory myositis, and autoimmune thyroid disease — suggesting that the ankyrin domain's protein-docking function is broadly relevant to B-cell-driven autoimmunity.

The Mechanism

The BANK1 protein contains ankyrin repeats (amino acids ~309–402) that mediate interactions with IP3 receptor 2 (IP3R2) and other signaling partners. IP3R2 phosphorylation by LYN (facilitated by BANK1 scaffolding) releases calcium from the endoplasmic reticulum — the calcium flux that sustains BCR activation and drives B-cell differentiation toward antibody production.

The alanine at position 383 is highly conserved across all mammals examined²² highly conserved across all mammals examined
Conservation extends to Monodelphis domestica (opossum), indicating strong evolutionary constraint on this residue across ~180 million years of mammalian evolution, which argues for functional importance. The G allele encodes the ancestral alanine (Ala383) — the common, risk-associated form. The A allele encodes threonine (Thr383), a polar residue with a hydroxyl group that introduces a subtle conformational change in the ankyrin fold.

Threonine at this position is thought to subtly alter how the ankyrin domain docks onto IP3R2 and possibly other interaction partners. Mutations in ankyrin motifs in related proteins have been shown to alter IP3R interactions and cytoplasmic calcium mobilization³³ alter IP3R interactions and cytoplasmic calcium mobilization
Ankyrin-B ankyrin repeat mutations disrupt Na,K-ATPase/IP3R signaling microdomains and are associated with cardiac arrhythmia in other biological contexts, providing a mechanistic precedent. The net effect is that the Thr383 (A allele) form may have subtly reduced scaffold efficiency, translating to a modest dampening of BCR-evoked calcium signaling and a protective effect against B-cell hyperactivation.

The Evidence

The variant was co-discovered with rs10516487 and rs17266594 in the original BANK1 GWAS⁴⁴ original BANK1 GWAS
Kozyrev et al. performed a genome-wide scan in European-ancestry SLE patients identifying three independent BANK1 variants by Kozyrev et al. (2008, PMID 18204447). Independent replication was confirmed in Hong Kong Chinese (949 SLE patients, 1,042 controls): OR=0.84 for the A allele (P=0.021), confirming the protective effect of Thr383 across ancestries.

In systemic sclerosis⁵⁵ systemic sclerosis
Allanore et al. studied BANK1 in diffuse cutaneous SSc across combined French and German Caucasian cohorts (n=2,432 individuals), the A allele showed OR=0.73 (95% CI 0.61–0.87) against diffuse cutaneous SSc, with an A-haplotype protective OR=0.70 (P=3.39×10⁻⁴). BANK1, IRF5, and STAT4 showed additive effects in SSc risk.

In rheumatoid arthritis⁶⁶ rheumatoid arthritis
Dominguez-Soto et al. pooled data from Spanish and Argentinean RA cohorts (pooled P=0.0009, OR=1.17), the G allele was elevated in patients across four cohorts. A subsequent trans-ethnic meta-analysis⁷⁷ trans-ethnic meta-analysis
Génin et al. pooled France, Spain, and Japan RA cohorts confirmed the G allele associates with RA individually (OR=1.11, P=0.012) and identified epistatic interaction with BLK rs13277113: in individuals with the BLK GG background, the BANK1 G allele increased RA risk to OR=1.21 (95% CI 1.04–1.41, P=0.015).

In a Chinese Han cohort, rs3733197 was the only BANK1 variant significantly associated with polymyositis/dermatomyositis⁸⁸ only BANK1 variant significantly associated with polymyositis/dermatomyositis
Wang et al. studied 363 PM and 654 DM patients plus 1,280 controls; three other BANK1 SNPs were non-significant (OR=0.81, 95% CI 0.70–0.94, P=0.0183), with stronger protection for PM/DM with interstitial lung disease (P=6.0×10⁻³). In autoimmune thyroid disease, the A allele showed OR=0.73 for Hashimoto's thyroiditis (P<0.05) in a Chinese cohort.

Practical Actions

The A383T variant is a risk modifier, not a deterministic cause of autoimmune disease. The G allele (Ala383) is the common reference form carried by approximately 70% of the global population — it represents a baseline of somewhat higher B-cell signaling capacity that, in combination with other genetic and environmental factors, tips the balance toward B-cell-driven autoimmunity. The protective A allele (Thr383) provides a modest dampening of this signaling.

Practical implications are similar to those of the BANK1 rs10516487 variant, since both affect the same B-cell hyperactivation pathway. Carriers of the GG genotype face the highest population-level BANK1 contribution to autoimmune risk. Since this variant is independently associated with RA (not just SLE/SSc), awareness extends beyond the lupus spectrum to include rheumatoid arthritis signs.

The BANK1/BLK epistatic axis is especially important: the RA risk from BANK1 A383T is substantially amplified in individuals who also carry BLK rs13277113 GG. If both variants are present, the combined recommendation is for earlier and more proactive autoimmune monitoring.

Interactions

BANK1 A383T (rs3733197) shows documented epistatic interaction with BLK rs13277113 in rheumatoid arthritis. The BLK rs13277113 G allele reduces BLK kinase expression in B cells; with reduced BLK activity scaffolded by the more active Ala383 BANK1 form, the BCR signaling complex appears to hypercompensate. In the BLK GG background, the BANK1 G allele yielded RA OR=1.21 (P=0.015) — roughly double the marginal effect size of either gene alone.

BANK1 A383T was also identified as interacting with BLK in SLE susceptibility analysis (rs3733197 × rs13277113 P(interaction)=0.037 in the original Kozyrev data), confirming this epistatic relationship across both RA and SLE. This places the BANK1/BLK axis as a shared mechanistic pathway for multiple autoimmune conditions.

The relationship to the co-shipped rs10516487 (R61H, N-terminal domain) is one of independent additive effects within the same gene. Both variants contribute to BCR signaling amplification through different structural domains — rs10516487 through scaffold complex size, rs3733197 through ankyrin-domain docking efficiency. Carrying risk alleles at both positions is expected to compound the B-cell hyperactivation phenotype, though formal compound analysis has not been published for A383T + R61H specifically.